ProShare Advisors LLC Makes New Investment in ASP Isotopes Inc. (NASDAQ:ASPI)

ProShare Advisors LLC purchased a new position in ASP Isotopes Inc. (NASDAQ:ASPI) in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 14,751 shares of the company’s stock, valued at approximately $67,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in ASPI. CenterBook Partners LP bought a new position in shares of ASP Isotopes in the fourth quarter worth about $6,800,000. Geode Capital Management LLC increased its stake in shares of ASP Isotopes by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 1,175,450 shares of the company’s stock worth $5,326,000 after purchasing an additional 57,027 shares during the period. Northern Trust Corp increased its stake in shares of ASP Isotopes by 15.5% in the fourth quarter. Northern Trust Corp now owns 435,688 shares of the company’s stock worth $1,974,000 after purchasing an additional 58,525 shares during the period. Nuveen Asset Management LLC increased its stake in shares of ASP Isotopes by 672.1% in the fourth quarter. Nuveen Asset Management LLC now owns 413,346 shares of the company’s stock worth $1,872,000 after purchasing an additional 359,811 shares during the period. Finally, Diametric Capital LP increased its stake in shares of ASP Isotopes by 4.1% in the fourth quarter. Diametric Capital LP now owns 303,855 shares of the company’s stock worth $1,376,000 after purchasing an additional 11,886 shares during the period. Institutional investors and hedge funds own 16.80% of the company’s stock.

ASP Isotopes Trading Up 8.3%

ASP Isotopes stock opened at $7.93 on Wednesday. ASP Isotopes Inc. has a 52 week low of $1.86 and a 52 week high of $9.33. The company has a debt-to-equity ratio of 0.80, a quick ratio of 7.54 and a current ratio of 7.55. The firm has a market capitalization of $595.24 million, a PE ratio of -13.00 and a beta of 3.40. The business’s 50-day simple moving average is $6.05 and its 200-day simple moving average is $5.45.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group lifted their price objective on ASP Isotopes from $8.50 to $11.00 and gave the stock a “buy” rating in a research note on Wednesday, May 21st.

Insider Activity at ASP Isotopes

In related news, COO Robert Ainscow sold 66,666 shares of the business’s stock in a transaction dated Tuesday, April 15th. The stock was sold at an average price of $5.75, for a total transaction of $383,329.50. Following the transaction, the chief operating officer now directly owns 1,553,326 shares in the company, valued at $8,931,624.50. The trade was a 4.12% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Paul Elliot Mann sold 316,667 shares of the business’s stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $5.75, for a total value of $1,820,835.25. Following the transaction, the chief executive officer now owns 7,948,787 shares in the company, valued at $45,705,525.25. This represents a 3.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 766,667 shares of company stock worth $4,358,502 over the last three months. Company insiders own 21.40% of the company’s stock.

ASP Isotopes Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.